BLTE (Belite Bio) EV-to-FCF: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLTE Belite Bio Inc BLTE
21 GF Score
Price $151.15
! 3 Warning Signs
View Full Analysis

What is Belite Bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Belite Bio's Enterprise Value is $5,547.63 Mil. Belite Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil. Therefore, Belite Bio's EV-to-FCF for today is .

The historical rank and industry rank for Belite Bio's EV-to-FCF or its related term are showing as below:

BLTE' s EV-to-FCF Range Over the Past 10 Years
Min: -149.76   Med: 0   Max: 0
Current: -149.27

BLTE's EV-to-FCF is ranked worse than
100% of 334 companies
in the Biotechnology industry
Industry Median: 15.69 vs BLTE: -149.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-16), Belite Bio's stock price is $151.15. Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.530. Therefore, Belite Bio's PE Ratio (TTM) for today is At Loss.


Belite Bio  (NAS:BLTE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Belite Bio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=151.15/-2.530
=At Loss

Belite Bio's share price for today is $151.15.
Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.530.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Belite Bio EV-to-FCF Related Terms


Belite Bio EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Belite Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio EV-to-FCF Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial 0.00 -59.85 -41.68 -63.42 -156.08

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -156.08 0.00

BLTE vs DFTX, LGND, XENE: EV-to-FCF Comparison

For the Biotechnology subindustry, Belite Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belite Bio EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Belite Bio's EV-to-FCF falls into.


BLTE
21GF Score
Belite Bio Inc BLTE
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio EV-to-FCF Calculation

Belite Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=5547.627/0
=

Belite Bio's current Enterprise Value is $5,547.63 Mil.
Belite Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Belite Bio Business Description

Other Exchanges D01:Germany
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
21GF Score

Get the complete analysis for BLTE

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$151.15
Price